Eugene Protzko, MD
Ophthalmology · Havre de Grace, MDNPI 1588666713
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,641 of the $5,442 with a category attached, or 66.9%. 25 manufacturers reported payments, led by Perrigo Company PLC at 31.2% of the total. Reporting peaked in 2019 at $2,922 and has fallen 89.0% since, to $322 in 2025.
Across 121 payments — averaging $44.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Perrigo Company PLC$2K
- Aerie Pharmaceuticals, Inc.$1K
- Bausch & Lomb Americas Inc.$418
- AbbVie$357
- Novartis$271
- Kala Pharmaceuticals, Inc.$271
- plus $1K from 19 others
Across 80 payments — averaging $12,203 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bausch & Lomb Americas Inc.$280K
- AbbVie$262K
- Bausch Health US, LLC$245K
- Oyster Point Pharma, Inc.$113K
- Glaukos Corporation$64K
- Osmotica Pharmaceutical Corp.$11K
- plus $3K from 1 others
What the payments were for
- Consulting fees$60011%
- Travel & lodging$1,18422%
- Food & beverage$3,64167%
- Gifts$170%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Perrigo Company PLC | 3 | $1,696 |
| Aerie Pharmaceuticals, Inc. | 10 | $1,043 |
| Bausch & Lomb Americas Inc. | 12 | $418 |
| AbbVie(2 entities) | 17 | $357 |
| Novartis | 14 | $271 |
| Kala Pharmaceuticals, Inc. | 9 | $271 |
| Sun Pharmaceutical Industries Inc. | 11 | $236 |
| Tarsus Pharmaceuticals, Inc. | 7 | $235 |
| Alcon | 9 | $164 |
| NEW World Medical,inc. | 1 | $148 |
| Harrow Eye, LLC | 5 | $118 |
| Kowa Research Institute, Inc. | 1 | $97 |
| Amgen | 3 | $56 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $50 |
| Johnson & Johnson Surgical Vision, Inc. | 3 | $41 |
| Biotissue Holdings Inc. | 2 | $36 |
| Oyster Point Pharma, Inc. | 2 | $35 |
| Thea Pharma Inc. | 1 | $25 |
| Glaukos Corporation | 1 | $24 |
| Sight Sciences, Inc. | 2 | $24 |
| Eyepoint US, Inc. | 1 | $22 |
| Dompe US, Inc. | 1 | $20 |
| Galderma Laboratories, L.p. | 1 | $19 |
| Tearlab Corp | 1 | $18 |
| Carl Zeiss Meditec, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,442 in reported general payments places this provider in the 80th percentile of 493 ophthalmology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 61 | $68,195 |
| Cyclosporine | 62 | $38,561 |
| LumiganBimatoprost | 37 | $25,796 |
| XiidraLifitegrast | 13 | $17,883 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 27 | $7,973 |
| Travoprost | 20 | $7,582 |
| Prednisolone Acetate | 143 | $5,305 |
| Latanoprost | 342 | $5,094 |
| VyzultaLatanoprostene Bunod | 14 | $4,950 |
| Loteprednol Etabonate | 17 | $3,355 |
| Timolol Maleate | 151 | $3,054 |
| Brimonidine Tartrate | 54 | $2,822 |
| Brinzolamide | 12 | $2,522 |
| Alphagan PBrimonidine Tartrate | 11 | $1,997 |
| Fluorometholone | 12 | $1,237 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Alphagan P | $357 | $95,988109 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $418 | $22,83427 claims |
| AlconSimbrinza | $164 | $7,97327 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $50 | $3,35517 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 493 ophthalmology providers in Maryland.
Other ophthalmology in Havre de Grace
- Jonathan SeidenbergHavre de Grace$32K
- Alfred SommerBaltimore$2.9M
- Richard AdlerBaltimore$2.7M
- Peter McDonnellBaltimore$1.4M
- Esen AkpekBaltimore$782K
- Lisa FeulnerBel Air$434K
- Allen HuHagerstown$379K
- Susan BresslerLutherville$341K
- Renee BovelleGlenn Dale$292K
- Neil BresslerBaltimore$265K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.